President Trump nominated Chris Klomp for deputy health secretary, solidifying his position as Health Secretary Robert F. Kennedy Jr.'s second-in-command. Klomp's prior role as Medicare director and chief counselor at HHS earned him praise from industry leaders. This nomination contributes to a growing list of Trump's health appointments awaiting Senate confirmation. Trump highlighted Klomp's strong leadership, entrepreneurial success, and trustworthiness in his announcement. He praised Klomp's performance leading Medicare and overseeing daily operations. Trump emphasized Klomp's business experience as beneficial for implementing significant reforms, particularly regarding drug prices. Klomp has been instrumental in filling critical vacancies at HHS, which underwent workforce changes and leadership overhauls. He previously led negotiations with pharmaceutical companies on "most favored nation" drug pricing policies. Before government service, Klomp worked for Bain & Company and Bain Capital. He also served as CEO of a health data firm called Collective Medical.